pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,678 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT808Endpoints607BioPharma Dive231onclive165Fierce Biotech75BioSpace74raps32fda press20globenewswire health
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology
  • STAT+: Wearables, and the flood of data they generate, inch closer to entering the clinic
    Wearables generate a lot of health data, but it exists outside the clinic for the most part. New moves from Oura and Whoop may change that.
    STAT · 1mo ago↗ source
  • Opinion: Why STAT is sticking with ‘health care’ as two words
    Is it “health care” or “healthcare”? STAT readers had strong feelings.
    STAT · 1mo ago↗ source
  • STAT+: Trump’s health care affordability czar touts Medicaid cuts to hospital leaders
    Hospital execs say they're working to mitigate the impacts of the looming cuts.
    STAT · 1mo ago↗ source
← prev
page 35 of 68
next →
20
fda recalls20
fda medwatch16
6
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
  • A leader of the 2014 U.S. Ebola response compares then to now
    As the world deals with an outbreak of Ebola that has no known cure, Susan Reichle, who last year co-founded Aid Transition Alliance to support former USAID professionals, discusses the…
    STAT · 1mo ago↗ source
  • STAT+: GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B
    GSK is buying Nuvalent, the maker of targeted cancer drugs, for $10.6 billion, a sizable addition to the latest run of biopharma acquisitions.
    STAT · 1mo ago↗ source
  • GSK to acquire Nuvalent and its two cancer drugs under FDA review for $10.6B
    GSK is making one of the largest biotech acquisitions in its history to gain access to two experimental lung cancer medicines that are due for FDA approval decisions later this year. The UK drugmak…
    Endpoints · 1mo ago↗ source
  • Alcohol study discarded by Trump officials is published in scientific journal
    A government-commissioned study had been meant to inform new dietary guidelines, and found risks associated with even light drinking.
    STAT · 1mo ago↗ source
  • Health workers at the epicenter of Congo’s Ebola outbreak labor with little pay or rest
    Health workers at the epicenter of Congo's Ebola outbreak are laboring with little pay or rest.
    STAT · 1mo ago↗ source
  • #ADA26: AstraZeneca's GLP-1 pill cuts weight by 10.5% after six months
    The race to be third to market with an obesity pill has a number of contenders, including Roche, Pfizer and Structure Therapeutics. On Monday, AstraZeneca set out its own stall with data on a pill ...
    Endpoints · 1mo ago↗ source
  • STAT+: AstraZeneca’s GLP-1 pill shows promise in obesity, diabetes trials
    AstraZeneca’s GLP-1 pill showed promise in mid-stage obesity and diabetes studies, but it may still be too early to determine how it stacks up against other oral treatments.
    STAT · 1mo ago↗ source
  • City banks nearly $100M for next-gen RNAi drugs
    Co-founded by longtime Alnylam CEO John Maraganore, City has brought a clotting disorder drug into early human testing. An experimental therapy for Stargardt disease could soon follow.
    BioPharma Dive · 1mo ago↗ source
  • Incyte CEO sees $2B Vega deal aiding a post-Jakafi future
    Bill Meury has been in or led the C-suite of several biopharma companies that have constructed multibillion-dollar exits over the past decade: Allergan, Karuna and Anthos. Now, he’s the one buying.…
    Endpoints · 1mo ago↗ source
  • City Therapeutics gets $99M to gather data on three RNAi medicines
    City Therapeutics, the next-gen RNAi startup founded and led by former Alnylam executives, has collected $99.5 million to fund the clinical development of its first three candidates and expand into…
    Endpoints · 1mo ago↗ source
  • Roche stakes $700M on Nurix’s protein-degrading drug
    Potentially worth up to $2.3 billion, the collaboration is a bet that drugs able to eliminate the “BTK” enzyme will prove superior to existing medicines that block its activity.
    BioPharma Dive · 1mo ago↗ source
  • GoHealth files for bankruptcy, as Medicare Advantage insurers pull back
    The volatile Medicare Advantage market can now count GoHealth as a casualty. GoHealth, a health insurance marketplace focused on seniors, on Sunday voluntarily filed for Chapter 11 bankruptcy in th…
    Endpoints · 1mo ago↗ source
  • Tango data add to growing momentum for pancreatic cancer drugs
    A combination involving Tango’s experimental therapy appeared to boost response rates in a small clinical trial well beyond what would be expected, sparking a share surge.
    BioPharma Dive · 1mo ago↗ source
  • Incyte to buy blood disorder drug in possibly $2B deal
    Acquiring Vega Therapeutics, an offshoot of "hub-and-spoke" biotech Star Therapeutics, would give Incyte a medicine that’s in late-stage testing and designed to control bleeding.
    BioPharma Dive · 1mo ago↗ source
  • J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for $1B
    The buyout hands J&J a technology that merges elements of two popular drugmaking methods: protein degraders and antibody-drug conjugates.
    BioPharma Dive · 1mo ago↗ source
  • Treeline to go public via reverse merger with Standard BioTools
    Treeline Biosciences has shared plans to debut on public markets through a reverse merger with Standard BioTools in a move that should give the company a cash runway through 2029. The
    Endpoints · 1mo ago↗ source
  • ADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option
    At a big meeting for weight loss drugs, Lilly’s “triple G” therapy set a new standard as lingering doubts surrounded other competing treatments.
    BioPharma Dive · 1mo ago↗ source
  • STAT+: UnitedHealthcare’s lactation billing feud, and fake strokes
    The biggest U.S. health insurer is changing how it pays for lactation counseling, and it could cut payment for many providers.
    STAT · 1mo ago↗ source
  • J&J makes $1B move for Firefly Bio, Carolyn Bertozzi's twist on ADCs in KRAS field
    Johnson & Johnson is making another early-stage oncology deal, dishing out $1 billion in cash to acquire Firefly Bio, a preclinical startup working on degrader antibody conjugates. J&J now joins th…
    Endpoints · 1mo ago↗ source
  • GSK inks multi-target pact with Engitix; Sangamo considers strategic options
    Plus news about Pfizer's latest label expansion. 🤝 GSK inks multi-target liver pact with Engitix: London-based Engitix will use disease models based on its extracellular matrix technology to ident…
    Endpoints · 1mo ago↗ source
  • Tango plans Phase 3 pancreatic cancer study after combo success
    Will 2026 be remembered as the year when pancreatic cancer finally became treatable? Following Revolution Medicines’ smashing success at the annual American Society of Clinical Oncology meeting las…
    Endpoints · 1mo ago↗ source
  • Coming Soon
    Next installments of the biopharma pay series coming soon
    Endpoints · 1mo ago↗ source